Status:
COMPLETED
I-Smads in Periodontitis
Lead Sponsor:
Bulent Ecevit University
Conditions:
Periodontitis
Treatment Adherence
Eligibility:
All Genders
25-55 years
Brief Summary
Recently, it has been stated that Smads play an active role in all conditions where transforming growth factor-beta (TGF-β) is involved, including periodontal inflammation. This study aimed to examine...
Eligibility Criteria
Inclusion
- Have at least 20 natural teeth, excluding third molars.
- Periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting \>30% of the teeth, as detected on clinical and radiographical examinations.
- Periodontally healthy control group had no sign of gingival inflammation, no PD \> 3mm and no evidence of attachment or bone loss
Exclusion
- History of systemic disease.
- Regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study.
- Periodontal treatment during last 6 months that could affect periodontal status.
- Smoking.
- History of radiotherapy or chemotherapy.
- Current pregnancy, lactation or menopause.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04846166
Start Date
August 1 2019
End Date
March 1 2020
Last Update
April 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Figen Öngöz Dede
Ordu, Turkey (Türkiye), 52100